

# Company Results Review

31 January 2007 | 7 pages

# IL & FS Investsmart (ILFI.BO)

# Sell: 3Q07 Results - Disappointing Quarter, No Revival Yet

- 3Q07 results: well below expectations Investsmart's 3Q07 profits of Rs83m are 49% lower than estimates and 58% and 33% lower yoy and sequentially. Operationally, no signs of a revival yet; it continues to lose market share and management still appears in transition. Maintain Sell/ Medium Risk.
- Lack of momentum, market share Though capital market volumes are up 30% qoq, Investsmart's revenues have declined 28% qoq. Where we were expecting only a modest revival, it has not come. Investsmart continues to lose market share, and the lack of business momentum this year has hit the core business hard. We see further flux, at least at the operational level, over the near term.
- E\*Trade has extended offer deadline, transition period E\*Trade has extended its open offer for 20% shares to 13<sup>th</sup> February, 2007. It is now the dominant shareholder and appears to be driving strategy and positioning over the medium term and possible upsides as well. Near term though, there still remains a period of transition and rebuilding.
- Fundamental value lower, recommend exit We believe the fundamental value is closer to our target price of Rs161. The current market price appears driven by the open offer price of Rs210; we recommend investors exit at the current price or during the offer period.

Sell/Medium Risk	3M
Price (31 Jan 07)	Rs204.55
Target price	Rs161.00
Expected share price return	-21.3%
Expected dividend yield	1.3%
Expected total return	-20.0%
Market Cap	Rs14,177M
	US\$322M

Price Performance	(RIC:	ILFI.BO,	BB:	ILFI IN)
-------------------	-------	----------	-----	----------




Figure 1. Statistica	I Abstract	(Rupees	Million)
----------------------	------------	---------	----------

Year to March	Net Profit (Rs Mils.)	FD EPS (Rs)	EPS Growth (%)	P/E (X)	P/BV (X)	ROAE (%)	ROAA (%)	Div Yld (%)
FY05	330.6	9.4	50%	21.6	8.2	44.4	17.0	1.1
FY06	691.2	13.6	44%	15.0	2.1	18.5	11.7	1.6
FY07E	674.1	10.1	-26%	20.3	1.9	9.9	6.8	1.3
FY08E	799.3	11.9	19%	17.1	1.8	10.9	7.6	1.3
FY09E	815.2	12.2	2%	16.8	1.7	10.2	7.3	1.3

Source: Citigroup Investment Research

Manish Chowdhary, CFA<sup>1</sup>

+91-22-6631-9853

manish.chowdhary@citigroup.com

Aditya Narain, CFA1

+91-22-6631-9879

aditya.narain@citigroup.com

Himani Shah<sup>1</sup>

himani.shah@citigroup.com

See page 5 for Analyst Certification and important disclosures.

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

¹Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2005	2006	2007E	2008E	2009E
Valuation Ratios					
P/E adjusted (x)	21.7	15.1	20.3	17.1	16.8
P/E reported (x)	21.7	15.1	20.3	17.1	16.8
P/BV (x)	8.3	2.1	1.9	1.8	1.7
P/Adjusted BV diluted (x)	8.3	2.1	1.9	1.8	1.7
Dividend yield (%)	1.1	1.6	1.3	1.3	1.3
Per Share Data (Rs)					
EPS adjusted	9.45	13.56	10.07	11.94	12.18
EPS reported	9.45	13.56	10.07	11.94	12.18
BVPS	24.75	98.68	105.52	114.46	123.64
Tangible BVPS	24.75	98.68	105.52	114.46	123.64
Adjusted BVPS diluted	24.75	98.68	105.52	114.46	123.64
DPS	2.33	3.22	2.73	2.73	2.73
Profit & Loss (RsM)					
Net interest income	5	51	287	365	378
Fees and commissions	1,098	2,010	1,857	2,152	2,408
Other operating Income	39	89	98	105	114
Total operating income	1,142	2,150	2,242	2,622	2,900
Total operating expenses	-652	-1,139	-1,219	-1,408	-1,661
Oper. profit bef. provisions	490	1,011	1,023	1,214	1,239
Bad debt provisions	0	-2	-6	-9	-9
Non-operating/exceptionals	-3	-4	0	0	0
Pre-tax profit	487	1,006	1,017	1,206	1,230
Tax	-156	-314	-343	-406	-414
Extraord./Min. Int./Pref. Div.	0	0	0	0	0
Attributable profit	331	691	674	799	815
Adjusted earnings	331	691	674	799	815
Growth Rates (%)					
EPS adjusted	49.6	43.6	-25.7	18.6	2.0
Oper. profit bef. prov.	63.1	106.3	1.2	18.7	2.0
Balance Sheet (RsM)					
Total assets	2,127	9,722	10,189	10,800	11,428
Avg interest earning assets	1,187	4,529	7,672	7,905	8,239
Customer loans	734	2,548	5,346	3,208	4,010
Gross NPLs	0	0	0	0	0
Liab. & shar. funds	2,127	9,722	10,189	10,800	11,428
Total customer deposits	0	0	0	0	0
Reserve for loan losses	0	0	0	0	0
Shareholders' equity	866	6,604	7,061	7,660	8,274
Profitability/Solvency Ratios (%)					
ROE adjusted	44.4	18.5	9.9	10.9	10.2
Net interest margin	0.4	1.1	3.7	4.6	4.6
Cost/income ratio	57.1	53.0	54.4	53.7	57.3
Cash cost/average assets	33.6	19.2	12.2	13.4	14.9
NPLs/customer loans	0.0	0.0	0.0	0.0	0.0
Reserve for Ioan Iosses/NPLs	na	na	na	na	na
Bad debt prov./avg. cust. loans	0.1	0.1	0.2	0.2	0.3
Loans/deposit ratio	na	na	na	na	na
Tier 1 capital ratio	na	na	na	na	na
Total capital ratio	na	na	na	na	na

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Figure 2. 3Q07 Results: Key Highlights (Rupees Million)							
	3Q07	3Q06	YoY %	2Q07	QoQ%		
Income from Operations	165	463	-64.4	228	-27.7		
Other Income	30	15	93.9	11	181.3		
Gross Total Income	195	479	-59.3	239	-18.4		
Interest expense	(15)	(3)	322.9	(4)	311.0		
Total Operating Income	180	475	-62.1	235	-23.4		
Operating Expenses	(39)	(185)	-78.8	(66)	-40.3		
Pre-Tax Profit	141	290	-51.5	169	-16.9		
Tax	(58)	(96)	-39.3	(46)	27.8		
Net Profit	83	194	-57.5	124	-33.4		
Source: Company Reports and Citigroup	Investment Research						

# IL & FS Investsmart

# Company description

IL&FS Investsmart was established as a fully owned subsidiary of IL&FS Ltd. in 1997. IL&FS is a Non-Banking Finance Company (NBFC) engaged in infrastructure lending, formulating policy and financing of infrastructure investments. E\*Trade has increased its stake in Investsmart to about 38% currently and is the single largest shareholder. Investsmart and its subsidiaries engage in various businesses including: retail and institutional brokerage, distribution of equity research products and third-party financial products such as mutual funds and insurance products, margin financing, project syndication, portfolio management, merchant banking and also commodity broking. Investsmart has also entered into insurance training through one of its subsidiaries. Investsmart operates through a franchisee business model in addition to its own branches, and has built a sizeable customer base of about 100,000 customers as at November 2006. The company operates in over 90 cities and over 210 offices.

## Investment thesis

We rate Investsmart Sell/Medium Risk (3M) with a target price of Rs161. Investsmart's 1H07 earnings have been below expectations due to a drop in secondary market volumes and sharp reduction in primary market and investment banking activity. Though the ban on new account openings has been lifted, the company has yet to pick up significant momentum on its core retail broking and margin finance businesses. E\*Trade now appears to be the dominant shareholder and would likely drive the strategy, positioning and growth over the medium term, however, over the immediate term, there is a likely period of transition.

We believe that E\*Trade adds longer-term value to the company in terms of a) an established and stronger brand, b) strategic positioning of the businesses and c) longer-term stronger growth, especially on the retail distribution franchise. In the immediate term, however, we see the business model still evolving and relative lack of strategic clarity for the different businesses including investment banking. E\*Trade has committed management resources to Investsmart, and we expect more strategic clarity and direction post completion of the open offer.

In the current context, however, we believe that the fundamental value of the

stock is lower at Rs161 and the stock price is supported by the open offer price of Rs210. We recommend investors exit at current prices or tender shares during the offer period.

### **Valuation**

Our target price of Rs161 is based on a 15% discount to the Sensex P/E on a 1-year forward multiple. We are increasing the discount to factor in lower capital market volumes and a meaningful slowdown in Investsmart's capital markets business. This translates into 14.6x 1-year forward EPS, or Rs161. We also benchmark Investsmart off a 1.4x 1-year forward P/BV for a 10% FY07E RoE. This translates into a fair value of Rs154. We apply a 65% discount to the Sensex 1-year forward P/BV of 4.0x (on a 23.7% expected RoE for FY07). We believe this discount factors in the substantially lower RoE that Investsmart earns. Our target price is based on our P/E-based valuation methodology, which we believe is appropriate given the relatively similar nature of Investsmart's capital markets businesses - both equity and debt - and it being largely feebased business.

#### Risk


We rate Investsmart as Medium Risk based on Investsmart's diversified capital markets franchise and the relatively low-risk approach of management - a franchise model and substantial capital infusion that lends a basic cushion to the business. Its ownership structure (i.e., a large domestic government-owned financial institution) also provides a slight hedge against any meaningful (though non-business related) developments, in our view. Key risks to our target price include the following: a) Its businesses and earnings are highly correlated to the capital markets, which could result in significant volatility. The capital markets related broking and IPO Finance businesses could perform better than expected. b) Margin financing - Faster expansion of margin finance portfolio and lower than expected losses on this portfolio. c) Earlier than expected execution of strategic expansion for the retail broking and distribution businesses.

# Analyst Certification Appendix A-1

We, Manish Chowdhary, CFA and Aditya Narain, CFA, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### IMPORTANT DISCLOSURES

# IL & FS Investsmart Ltd (ILFI.BO)



Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of IL & FS Investsmart Ltd.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from IL & FS Investsmart Ltd.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from IL & FS Investsmart Ltd in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): IL & FS Investsmart Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: IL & FS Investsmart Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: IL & FS Investsmart Ltd.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 31 December 2006	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3106)	43%	41%	15%
% of companies in each rating category that are investment banking clients	45%	41%	34%
India Asia Pacific (118)	58%	14%	28%
% of companies in each rating category that are investment banking clients	48%	50%	39%

#### **Guide to Fundamental Research Investment Ratings:**

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 15%-30% for High-Risk sto

10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

## OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 31 January 2007 04:00 PM on the issuer's primary market.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of equity securities of IL & FS Investsmart Ltd.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes o

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany. by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong, The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the

Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street. Sandton, 2196. Saxonwold, Citigroup Global Markets (Ptv) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST